Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright's target price points to a potential upside of 72.79% from the stock's previous close.
Several other analysts also recently commented on the company. Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company. UBS Group assumed coverage on Altimmune in a report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.71.
Read Our Latest Stock Analysis on Altimmune
Shares of ALT stock traded up $0.12 during mid-day trading on Wednesday, hitting $6.95. The company's stock had a trading volume of 910,688 shares, compared to its average volume of 2,315,350. The company has a market cap of $493.93 million, a PE ratio of -4.47 and a beta of 0.22. The company's fifty day simple moving average is $7.97 and its 200-day simple moving average is $7.21. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84.
Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter. During the same period last year, the company earned ($0.39) EPS. On average, equities analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC purchased a new stake in shares of Altimmune during the 3rd quarter worth approximately $31,000. 180 Wealth Advisors LLC purchased a new stake in Altimmune in the fourth quarter worth $78,000. PFG Investments LLC bought a new stake in shares of Altimmune in the fourth quarter valued at $96,000. XTX Topco Ltd purchased a new position in shares of Altimmune during the 2nd quarter valued at $96,000. Finally, DRW Securities LLC bought a new position in shares of Altimmune during the 2nd quarter worth $112,000. Institutional investors own 78.05% of the company's stock.
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.